|
1) Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009; 32: 3-107
|
|
|
|
2) Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008; 7: 399-410
|
|
|
|
|
3) Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997; 10: 1-8
|
|
|
|
|
|
4) Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007; 49: 1157-63
|
|
|
|
|
|
5) Drummond W, Munger MA, Rafigue Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich). 2007; 9: 742-50
|
|
|
|
|
|
6) Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007; 25: 217-26
|
|
|
|
|
|
7) Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370: 221-9
|
|
|
|
|
|
8) Dong YF, Liu L, Kataoka K, et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia. 2010; 53: 180-91
|
|
|
|
|
|
9) Singh VP, Le B, Khode R, et al. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57: 3297-306
|
|
|
|
|
|
10) Dong YF, Liu L, Lai ZF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010; 28: 1554-65
|
|
|
|
|
|
11) Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008; 52: 130-6
|
|
|
|
|
|
12) Yamamoto E, Kataoka K, Dong YF, et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009; 54: 633-8
|
|
|
|
|
|
13) Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008; 118: 984-93
|
|
|
|
|
|
14) Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclero-tic changes. Hypertension. 2008; 52: 563-72
|
|
|
|
|
|
15) Ino J, Kojima C, Osaka M, et al. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol. 2009; 29: 1858-63
|
|
|
|
|
|
16) Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008; 73: 1419-25
|
|
|
|
|
|
17) Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358: 2433-46
|
|
|
|
|
|
18) Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009; 32: 1873-9
|
|
|
|
|
|
19) Persson F, Rossing P, Reinhard H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia. 2010; 53: 1576-80
|
|
|
|
|
|
20) Cherney DZ, La V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care. 2010; 33: 361-5
|
|
|
|
|
|
21) McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1: 17-24
|
|
|
|
|
|
22) Solomon SD, Applbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009; 119: 530-7
|
|
|
|
|
|
23) Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109: 1417-27
|
|
|
|
|
|
24) Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006; 69: 105-13
|
|
|
|
|
|
25) Saris JJ, t Hoen PA, Garrelds IM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension. 2006; 48: 564-71
|
|
|
|
|
|
26) Danser AH. (Pro)renin receptors: are they biologically relevant？ Curr Opin Nephrol Hypertens. 2009; 18: 74-8
|
|
|
|
|
|
27) Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 2008; 51: 682-8
|
|
|
|
|
|
28) Schefe JH, Neumann C, Goebel M, et al. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens. 2008; 26: 1787-94
|
|
|
|
|